Publication details

<< back
 

CLINICAL IMPLICATION OF HYPERDIPLOIDY/NON-HYPERDIPLOIDY IN MM PATIENTS TREATED BY NEWER DRUGS

Basic information
Original title:CLINICAL IMPLICATION OF HYPERDIPLOIDY/NON-HYPERDIPLOIDY IN MM PATIENTS TREATED BY NEWER DRUGS
Authors:Jan Smetana, Petr Kuglík, Romana Zaoralová, Henrieta Grešliková, Pavel Němec, Renata Kupská, Hana Filková, Luděk Pour, Lenka Zahradová, Michal Holánek, Zdeněk Adam, Roman Hájek
Further information
Citation:SMETANA, Jan, Petr KUGLÍK, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Renata KUPSKÁ, Hana FILKOVÁ, Luděk POUR, Lenka ZAHRADOVÁ, Michal HOLÁNEK, Zdeněk ADAM and Roman HÁJEK. CLINICAL IMPLICATION OF HYPERDIPLOIDY/NON-HYPERDIPLOIDY IN MM PATIENTS TREATED BY NEWER DRUGS. In XIIth International Myeloma Workshop, Washington DC. 2009. ISBN 1557-9190.Export BibTeX
@proceedings{824206,
author = {Smetana, Jan and Kuglík, Petr and Zaoralová, Romana and Grešliková, Henrieta and Němec, Pavel and Kupská, Renata and Filková, Hana and Pour, Luděk and Zahradová, Lenka and Holánek, Michal and Adam, Zdeněk and Hájek, Roman},
booktitle = {XIIth International Myeloma Workshop, Washington DC},
keywords = {multiple myeloma; cytogenetics, hyperdiploidy, FISH, array-CGH, new drugs},
language = {eng},
isbn = {1557-9190},
title = {CLINICAL IMPLICATION OF HYPERDIPLOIDY/NON-HYPERDIPLOIDY IN MM PATIENTS TREATED BY NEWER DRUGS},
year = {2009}
}
Original language:English
Field:Oncology and hematology
Type:Conference abstract
Keywords:multiple myeloma; cytogenetics, hyperdiploidy, FISH, array-CGH, new drugs

Multiple myeloma (MM) is a haematological disease characterised by accumulation of changed clone of plasma cells (myeloma cells) in bone marrow. This disorder is currently incurable and therefore there is a need for searching new prognostic factors, which are suitable for treatment optimalization. Among the most significant factors in multiple myeloma diagnosis belong cytogenetic changes. The main aim of this work was investigation of bone marrow samples from 74 MM patients treated by new drugs (Velcade/Thalidomid) for presence of hyperdiploidy / non-hyperdiploidy. Partial aims were focused on both comparison of incidence another prognostic important chromosomal MM abnormalities (translocation t(4;14); deletion 13q14, deletion 17p13 and gain/amplification 1q21) between hyperdiploid and non-hyperdiploid group of patients and comparison of impact of hyperdiploidy / non-hyperdiploidy on disease prognosis using survival analyses of both groups of patients.

Related projects:

 
 
top